A Disproportionality Analysis of the Adverse Drug Events Associated with Lurasidone in Paediatric Patients Using the US FDA Adverse Event Reporting System (FAERS).

Prasad Nishtala; Teyuan Chyou

doi:10.1007/s40264-020-00928-1

A Disproportionality Analysis of the Adverse Drug Events Associated with Lurasidone in Paediatric Patients Using the US FDA Adverse Event Reporting System (FAERS).

Prasad Nishtala, Teyuan Chyou

Department of Life Sciences

University of Otago

Research output: Contribution to journal › Letter › peer-review

9 Citations (SciVal)

51 Downloads (Pure)

Original language	English
Pages (from-to)	607-609
Number of pages	3
Journal	Drug Safety
Volume	43
Issue number	6
DOIs	https://doi.org/10.1007/s40264-020-00928-1
Publication status	Published - 4 Apr 2020

Bibliographical note

Rees, K.E., Chyou, T. & Nishtala, P.S. A Disproportionality Analysis of the Adverse Drug Events Associated with Lurasidone in Paediatric Patients Using the US FDA Adverse Event Reporting System (FAERS). Drug Saf (2020). https://doi.org/10.1007/s40264-020-00928-1

ASJC Scopus subject areas

Toxicology
Pharmacology
Pharmacology (medical)

Access to Document

10.1007/s40264-020-00928-1

Lurasidone_Author accepted copy

Cite this

@article{d73505060cc7493e9e1e9e56f16b05f4,

title = "A Disproportionality Analysis of the Adverse Drug Events Associated with Lurasidone in Paediatric Patients Using the US FDA Adverse Event Reporting System (FAERS).",

author = "Prasad Nishtala and Teyuan Chyou",

note = "Rees, K.E., Chyou, T. & Nishtala, P.S. A Disproportionality Analysis of the Adverse Drug Events Associated with Lurasidone in Paediatric Patients Using the US FDA Adverse Event Reporting System (FAERS). Drug Saf (2020). https://doi.org/10.1007/s40264-020-00928-1",

year = "2020",

month = apr,

day = "4",

doi = "10.1007/s40264-020-00928-1",

language = "English",

volume = "43",

pages = "607--609",

journal = "Drug Safety",

issn = "0114-5916",

publisher = "Adis",

number = "6",

}

TY - JOUR

T1 - A Disproportionality Analysis of the Adverse Drug Events Associated with Lurasidone in Paediatric Patients Using the US FDA Adverse Event Reporting System (FAERS).

AU - Nishtala, Prasad

AU - Chyou, Teyuan

N1 - Rees, K.E., Chyou, T. & Nishtala, P.S. A Disproportionality Analysis of the Adverse Drug Events Associated with Lurasidone in Paediatric Patients Using the US FDA Adverse Event Reporting System (FAERS). Drug Saf (2020). https://doi.org/10.1007/s40264-020-00928-1

PY - 2020/4/4

Y1 - 2020/4/4

UR - http://www.scopus.com/inward/record.url?scp=85084635687&partnerID=8YFLogxK

U2 - 10.1007/s40264-020-00928-1

DO - 10.1007/s40264-020-00928-1

M3 - Letter

SN - 0114-5916

VL - 43

SP - 607

EP - 609

JO - Drug Safety

JF - Drug Safety

IS - 6

ER -

A Disproportionality Analysis of the Adverse Drug Events Associated with Lurasidone in Paediatric Patients Using the US FDA Adverse Event Reporting System (FAERS).

Bibliographical note

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this